Michael P. Poirier

Mr. Michael P. Poirier

Saint Louis University, St. Louis, Missouri, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
DSDivya S. Subramaniam
Divya S. Subramaniam
ZZZidong Zhang
Zidong Zhang
ZTZachary Timmer
Zachary Timmer
EDElisabeth DeMarco
Elisabeth DeMarco
Michael P. PoirierMichael P. Poirier
Michael P. Poirier
LHLeslie Hinyard
Leslie Hinyard
Introduction: Palliative care (PC) utilization remains low among pancreatic cancer patients. This study explores the association of PC with mental health service and pharmacotherapy utilization among pancreatic cancer patients. Methods: Retrospective analysis was conducted on a sample of patients in the United States with newly diagnosed pancreatic cancer using Electronic Health Record data from Optum’s Integrated Claims-Clinical data set. Subsequent diagnoses of anxiety and depression and PC consultation encounters were determined using ICD-9/10 codes. Adjusted associations of mental health treatments with PC and patient characteristics were quantified using multiple logistic regression. Results: Among newly diagnosed pancreatic cancer patients (n = 4029), those with PC consultations exhibited a higher prevalence of anxiety (33.9% vs. 22.8%) and depression (36.2% vs. 23.2%). Mental health service use and pharmacotherapy varied, with the highest utilization among patients having both anxiety and depression. Treatment pattern was also influenced by age (aOR 1.832 for age <55 vs. 65–70 years). Notably, PC consultations showed no significant effect on the likelihood of documented treatment. Discussion: Our study emphasizes underutilization of PC and MH treatment for pancreatic cancer patients. These findings imply a crucial need for further investigation into palliative care’s role in addressing mental health concerns among pancreatic cancer patients.

20 February 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
ARAnanya Ravi
Ananya Ravi
EDElisabeth DeMarco
Elisabeth DeMarco
SGSarah Gebauer
Sarah Gebauer
Michael P. PoirierMichael P. Poirier
Michael P. Poirier
LHLeslie Hinyard
Leslie Hinyard
Osteoarthritis (OA) is the most common joint disease in the US and can increase the risk of depression. Both depression and OA disproportionately affect women, yet this study is one of few on depression prevalence, treatment across age groups, and predictors in women with OA. Data were extracted from the 2011–March 2020 National Health and Nutrition Examination Survey (NHANES). Women aged ≥ 45 years with self-reported osteo- or degenerative arthritis were included. Outcomes were depression (assessed with PHQ-9) and treatment (self-reported pharmacotherapy and mental health services). Logistic regression was used to examine associations between age group, covariates, and outcomes. Overall, depression prevalence was 8%, with higher proportions among those 45–64 years old. Aging was associated with reduced odds of depression (Age 65–79: OR 0.68 (95% CI: 0.52–0.89); Age 80+: OR 0.49 (95% CI: 0.33–0.74); vs. Age 45–54). Of those with a positive depression screen, 21.6% documented some form of treatment. Age group was not statistically different between those treated and those not treated. Women aged 45–64 with osteoarthritis may be at increased risk of depression, and most are not treated. As depression is related to increased pain and risk of rehospitalization, future research should prioritize interventions to increase uptake of depression treatment.